The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
about
Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient PlasmaComparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyA potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinomaManagement of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report.Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib.Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Afatinib in advanced NSCLC: a profile of its use.Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.Transformation to small cell lung cancer after first-line afatinib treatment.Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase.YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?A Study of Diagnostic Accuracy Using a Chemical Sensor Array and a Machine Learning Technique to Detect Lung CancerThe roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications
P2860
Q27853391-DC00D203-7B3A-4727-9D21-1E350E8E722EQ28069708-5AA3C9AC-7DF2-4295-BB9F-FDEA9B501731Q31160116-71E061DA-3781-49BF-84A8-3FCED1FDFCE2Q33703063-250AAA14-9B52-4880-B5B6-D90D808711A6Q33751194-0A472BD5-6690-43F9-9499-10156DD73E33Q33757134-135EFE7A-55B3-45C2-91F4-7C90EC98A99CQ37528312-22DA2952-F76D-46D0-A2B2-AEFD8E9DB4D5Q37650711-D60E13C5-1EDC-42DE-8F7D-A6E2386BA63CQ37698613-F6B54C61-730F-4EA8-AF25-986B4DB5F66AQ37709001-04A4A12A-B049-42A2-BCA9-E20803538C19Q38685481-48DC55BB-B9F8-4ED6-BE54-82F0B039D7D8Q38790929-53E45F0F-9BFA-475D-910A-8AFB9556C387Q38990576-E8F40DAE-8371-441E-9250-AD87AA59FBF0Q40979412-42A0DD6C-273E-4A1F-93C3-B7C9950FD2ADQ41001615-94922CDF-957F-450F-8718-E0BB3FB69B77Q41281151-0577E001-9CD3-440E-B178-A3C927141AF4Q41471047-89FC5170-EC65-4D1A-AD2D-033AE96B548BQ41561392-57A556C5-86FA-4538-8D9E-F072E9B25D30Q41601469-3604804B-E9DE-4B44-A3DB-731D89B2719EQ41709251-DD931A0D-735E-43EF-8B62-CBB28D971615Q42017572-BE2A01BF-99DE-4EE3-B7B3-5C12AE3438D3Q42378470-16B3165C-7F4F-471F-9C28-7A06EF8F7A95Q47102256-31D84ACE-73F5-41BB-AD70-E73B77C81EEBQ47130691-2396406F-90BE-4F89-A6B4-3C3DDBC18150Q47138128-38E82131-7191-4BDF-B5CD-6F7D9AE1A4FBQ47146662-A98BA77B-EB4D-4115-A503-4EC957171385Q47260594-BADDC8E3-607A-4AE2-AB6F-C713120E8B0AQ47564950-4E9D3BED-3097-4972-AF82-7E81C3699848Q48263612-B6721E5F-05F7-4165-969E-47B1796D1008Q49300205-F2036D1C-A9C5-46AA-A521-29CF4FB909F2Q49887989-1A91FCE1-333A-4D87-AC22-CA0147D9F17FQ50073382-F0798B1B-9413-46C9-9C26-9FEF65FD18DEQ52655265-7C784D2A-9525-4DD2-BF8E-299893A00CD8Q54976883-920B3635-5736-457B-837E-C09C99A6D68CQ54979885-C114A919-E30C-458D-AC06-D6627310ABE4Q55509033-BA56575C-848D-4A86-BFEE-0B8A21E7A63DQ55634316-9C824991-3839-4A9C-B17D-A853B30BF001Q58582629-BD428750-89C8-4654-86EE-3E264A614DBFQ58697268-41FCC1E2-C223-47DA-8732-8815C5E90381Q58741629-C1A6B7AB-206F-43FB-A60B-929D3CB912CD
P2860
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The mechanism of acquired resi ...... n lung adenocarcinoma patients
@en
The mechanism of acquired resi ...... lung adenocarcinoma patients.
@nl
type
label
The mechanism of acquired resi ...... n lung adenocarcinoma patients
@en
The mechanism of acquired resi ...... lung adenocarcinoma patients.
@nl
prefLabel
The mechanism of acquired resi ...... n lung adenocarcinoma patients
@en
The mechanism of acquired resi ...... lung adenocarcinoma patients.
@nl
P2093
P2860
P356
P1433
P1476
The mechanism of acquired resi ...... n lung adenocarcinoma patients
@en
P2093
James Chih-Hsin Yang
Jin-Yuan Shih
Meng-Feng Tsai
Pan-Chyr Yang
Shang-Gin Wu
Yi-Nan Liu
Yueh-Feng Wen
P2860
P304
12404-12413
P356
10.18632/ONCOTARGET.7189
P407
P577
2016-03-01T00:00:00Z